Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of US$ 80/g
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name | Tacrolimus |
CAS NO. | 104987-11-3 |
Purity | 99% |
Density | 1.19 |
Appearance and shape | White powder |
Tacrolimus, also known as FK506, is a fermentation product isolated from Streptomyces. It is a macrolide antibiotic and a powerful new immunosuppressant, mainly by inhibiting interleukin-2 The release of (IL-2) completely inhibits the effect of T lymphocytes, which is 100 times stronger than cyclosporine (CsA).
Immunosuppression in Transplantation: Tacrolimus is a potent immunosuppressant primarily used to prevent organ rejection in transplant patients, including those undergoing kidney, liver, heart, and other solid organ transplants.
Treatment of Autoimmune Diseases: It may also be prescribed in select cases to treat autoimmune disorders, where the immune system mistakenly attacks healthy body tissues, helping to control the overactive immune response.
Atopic Dermatitis Management: In dermatology, tacrolimus is formulated as a topical ointment or cream for the treatment of atopic dermatitis (eczema), reducing inflammation and itching.
Inhibits T-Cell Activation: Tacrolimus binds to the FKBP12 (FK506-binding protein 12) receptor complex, inhibiting the activation of calcineurin, a critical enzyme in T-cell activation and proliferation. This prevents the immune system from mounting a strong response against foreign bodies like transplanted organs.
Suppresses Cytokine Production: By inhibiting T-cell activation, tacrolimus also reduces the production of cytokines, which are signaling molecules that promote inflammation and immune responses. This contributes to its immunosuppressive effects.
Promotes Graft Acceptance: By suppressing the immune system's ability to reject transplanted tissue, tacrolimus allows the graft to be accepted by the recipient's body, reducing the risk of rejection and improving transplant success rates.